天津医药

• 综述 • 上一篇    下一篇

调节性树突状细胞的获取途径及其诱导免疫耐受的临床应用

李颖曦1,陈丹2,李克秋3,李光4   

  1. 1. 天津医科大学基础医学院医用生物学教研室
    2. 天津医科大学基础医学院药理学教研室
    3. 天津医科大学基础医学院生物学教研室
    4. 天津医科大学医用生物学教研室
  • 收稿日期:2014-01-06 修回日期:2014-02-17 出版日期:2014-07-15 发布日期:2014-07-15
  • 通讯作者: 李颖曦

Strategies for Generating Regulatory Dendritic Cells and the Clinical Application of Immune Tolerance

  • Received:2014-01-06 Revised:2014-02-17 Published:2014-07-15 Online:2014-07-15

PDF (PC)

2987

摘要：

【摘要】树突状细胞（DCs）是体内作用最强的抗原提呈细胞，具有双向免疫调节功能，既可诱导免疫应答，又可诱导免疫耐受。调节性树突状细胞（DCreg）具有负向免疫调节功能，可降低T细胞的免疫活性，诱导免疫耐受。 DCreg可通过不同机制经药物、细胞因子、局部微环境产生，其诱导的免疫耐受作用在器官移植、自身免疫性疾病中具有重要的临床意义。近期，DCreg的耐受性和安全性已在1型糖尿病和类风湿关节炎的临床试验中得到证实。本文就DCreg的获取途径及其诱导免疫耐受的临床应用综述如下。

关键词: 免疫耐受, 器官移植, 糖尿病, 1型, 关节炎, 类风湿, T淋巴细胞, 调节性树突状细胞

Abstract: Dendritic cells (DCs) are potent antigen presenting cells with dual functions in immune response or immune tolerance. Regulatory dendritic cells (DCreg) have negative immunomodulation effects. They can inhibit T cell stimulatory activity and induce immune tolerance. DCreg could be generated by the induction of drugs, cytokines and cell microenvironment with different mechanisms. The tolerance that DCreg induced is of great clinical significance in organ transplantation and autoimmune disease. Recently, several clinical trials have been conducted in type 1 diabetes and rheumatoid arthritis, with results that emphasize the tolerance and safety of DCreg therapy. In this review, we will focus on the strategies for generating DCreg and the clinical application of immune tolerance.

Key words: Immune tolerance, Organ transplantation, Diabetes mellitus, type 1, Arthritis, rheumatoid, T-lymphocytes, 调节性树突状细胞